Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead

Mantle cell lymphoma (MCL) is a heterogeneous aggressive disease and remains incurable with current chemotherapies. The development of monoclonal antibody (mAb) has led to substantial achievement in immunotherapeutic strategies for B-cell lymphomas including MCL. Nonetheless, progress in the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ming, Zhang, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475712/
https://www.ncbi.nlm.nih.gov/pubmed/31016256
http://dx.doi.org/10.1016/j.heliyon.2019.e01297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475712/
https://www.ncbi.nlm.nih.gov/pubmed/31016256
http://dx.doi.org/10.1016/j.heliyon.2019.e01297

Ejemplares similares